Get 40% Off
These stocks are up over 10% post earnings. Did you spot the buying opportunity? Our AI did.Read how

Uber notches upgrade ahead of Q3 earnings: 4 big analyst picks

Published 11/03/2023, 06:10 AM
© Reuters

Investing.com — Here is your Pro Recap of the biggest analyst picks you may have missed since yesterday: upgrades at Uber, Moderna , Zillow , and Aptiv.

InvestingPro subscribers got this news first. Never miss another market-moving headline.

Uber earns an upgrade ahead of Q3 earnings

KeyBanc upgraded Uber Technologies (NYSE:UBER) to Overweight from Sector Weight with a price target of $60.00, as reported in real-time on InvestingPro.

Uber's stock climbed over 6% yesterday following an announcement by New York's attorney general that the ride-sharing company will pay a $290 million settlement to conclude a multi-year investigation. The investigation had accused Uber of systematically cheating drivers out of pay and benefits.

The company is set to report its Q3/23 earnings on Nov 7. Street estimates stand at $0.07 for EPS and $9.54 billion for revenues.

Moderna raised to Hold at HSBC

HSBC upgraded Moderna (NASDAQ:MRNA) to Hold from Reduce with a price target of $69.00 (from $89.00) following the company’s reported Q3 results yesterday.

Moderna posted Q3 EPS of ($9.53), significantly worse than the consensus estimate of ($1.90), impacted by a $3.1 billion charge related to resizing and a tax valuation allowance. It includes $1.3B for inventory write-downs related to excess and obsolete COVID-19 products.

The company sees fiscal 2023 revenue of at least $6B, compared to the consensus of $6.45B, reflecting weaker demand for COVID-19 vaccines. Additionally, Moderna has delayed the launch of its flu shot to 2025, previously scheduled for 2024. As a result, shares plunged more than 6% yesterday.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

"The company’s medium-term revenue is still driven by its respiratory vaccines, where the dynamic will gradually shift from COVID-19 towards RSV and combo vaccines. Moderna plans to launch its RSV vaccine in 2024,” commented HSBC.

InvestingPro | Always Know First

Zillow raised at CFRA following Q3 earnings

CFRA upgraded Zillow (NASDAQ:ZG) Group (NASDAQ:Z) to Strong Buy from Buy with a price target of $47.00.

Shares fell more than 2% yesterday following the company’s reported Q3 results. Revenue grew 3% year-over-year to $496 million, beating the consensus estimate of $481.06M. Meanwhile, the residential revenue of $362M fell 3% year-over-year, although it outperformed the high end of the company's expectations.

Aptiv upgraded at Piper Sandler following the Q3 report

Piper Sandler upgraded Aptiv (NYSE:APTV) to Neutral from Underweight with a price target of $80.00 (from $82.00) following the company’s reported Q3 beat. However, the market reacted negatively to the quarterly report, with the stock dropping more than 10% yesterday.

According to Piper Sandler, this downturn is seen as a continuation of a sell-off trend that started in August. Considering Aptiv's stock is now hovering near the revised price target of $80, the analysts believe it is time to temper its bearishness, hence the upgrade to a Neutral rating.

“We still doubt Aptiv's ability to achieve long-term operating margin guidance of ~17%, but we also think investors are fretting too much about a delay in electric vehicle launch activity. Our estimates are moving downward to reflect a slower EV ramp, but not by enough to justify staying Underweight," commented Piper Sandler.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

In fast-moving markets, every second counts - and InvestingPro subscribers are always one step ahead with lightning-quick updates.

Start your free 7-day trial now.

InvestingPro | Be The First To Know

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.